Amgen faces first Neulasta biosimilar rival as FDA approves Mylan drugAmgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar Share XAmgen faces first Neulasta biosimilar rival as FDA approves Mylan drughttps://pharmaphorum.com/news/amgen-neulasta-biosimilar-fda-mylan-fulphila/
Fourth Humira biosimilar set for EU approvalEuropean regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s Share XFourth Humira biosimilar set for EU approvalhttps://pharmaphorum.com/news/humira-biosimilar-eu-sandoz-chmp/
GSK collaborates on AI-driven drug design with Cloud PharmaceuticalsGlaxoSmithKline (GSK) is set to apply artificial intelligence (AI) technology to improve its drug discovery efforts through a Share XGSK collaborates on AI-driven drug design with Cloud Pharmaceuticalshttps://pharmaphorum.com/news/gsk-ai-drug-design-cloud-pharmaceuticals/
UCB collaborates with Science 37 on virtual clinical trialsUCB is changing the way it conducts some of its research studies, removing the need for patients to Share XUCB collaborates with Science 37 on virtual clinical trialshttps://pharmaphorum.com/news/ucb-science-37-virtual-clinical-trials/
Pfizer eyes AI-powered drug discovery and development softwarePfizer has partnered with a ‘computation-driven’ pharmaceutical technology company to develop a drug discovery platform powered by artificial Share XPfizer eyes AI-powered drug discovery and development softwarehttps://pharmaphorum.com/news/pfizer-ai-drug-discovery-xtalpi/
Gilead to collaborate with Google’s Verily in inflammatory diseasesGilead has signed a three-year deal with Google’s life science division Verily to work on identifying the immunological Share XGilead to collaborate with Google’s Verily in inflammatory diseaseshttps://pharmaphorum.com/news/gilead-google-verily-inflammatory-disease-research/
Novo Nordisk ties discounts to adherence in SMS pilotNovo Nordisk is working with a digital health start-up to link better medication adherence to lower medicine costs Share XNovo Nordisk ties discounts to adherence in SMS pilothttps://pharmaphorum.com/news/novo-nordisk-sempre-health-sms-adherence/
Boehringer Ingelheim rolls-out COPD digital adherence programmeBoehringer Ingelheim has expanded access to a digital adherence programme that helps COPD patients take their medicines as Share XBoehringer Ingelheim rolls-out COPD digital adherence programmehttps://pharmaphorum.com/news/boehringer-copd-digital-adherence/
Novartis and Pear to develop substance use digital therapeuticsNovartis is set to develop and commercialise a range of digital therapeutics for patients with substance and opioid Share XNovartis and Pear to develop substance use digital therapeuticshttps://pharmaphorum.com/news/novartis-digital-therapeutics-sandoz-pear/
